Manu Chakravarthy, MD, PhD, is a physician-scientist with more than a decade of experience in academic and pharmaceutical research and development, and oversees the external innovation efforts across the value chain of diabetes and cardiometabolic diseases at Eli Lilly & Co. In this role, he is responsible for establishing academic collaborations and consortia management, identification and evaluation of product opportunities, in-/out-licensing efforts, project leadership, and scientific strategy. His prior industry experience at Merck & Co., included both early- (discovery, experimental medicine, clinical pharmacology, biomarker development) and late-stage drug development across several therapeutic areas. Dr. Chakravarthy received his MD and PhD degrees from the University of Texas at Houston, his internal medicine training at the University of Pennsylvania, and endocrinology fellowship at Washington University School of Medicine in St. Louis. His research has helped elucidate the role of de novo lipogenesis via fatty acid synthase in hepatic steatosis and metabolic disease, including the discovery of an endogenous ligand for the nutritionally regulated transcription factor, PPARalpha. Dr. Chakravarthy is Board-certified in Endocrinology, Diabetes & Metabolism and is an adjunct clinical asst. Professor at the Rutgers School of Medicine, NJ.